nach oben

Erschienen in:

23.10.2023

Developing Strategies to Improve the Efficacy of CAR-T Therapy for Acute Myeloid Leukemia

verfasst von: Shujing Guo, MMed, Xuejin Gao, MD, Mahara Sadhana, MMed, Ruiting Guo, MMed, Jile Liu, MMed, Wenyi Lu, MD, Ming Feng Zhao, MD

Erschienen in: Current Treatment Options in Oncology | Ausgabe 11/2023

Einloggen, um Zugang zu erhalten

Opinion statement

Acute myeloid leukemia (AML) is a fatal blood malignancy. With the development of immunotherapy, particularly chimeric antigen receptor T cells (CAR-T), the treatment of AML has undergone a significant change. Despite its advantages, CAR-T still faces a number of limitations and challenges while treating AML. Finding novel targets, altering the structure of CAR to increase efficacy while lowering side effects, and using double-target CAR and logic circuits are typical examples of key to answer these problems. With the advancement of gene editing technology, gene editing of tumor cells or normal cells to create therapeutic effects has grown in popularity. Additionally, the combination of multiple drugs is routinely used to address some of the obstacles and difficulties associated with CAR-T therapy. The review’s primary goal was to summarize recent strategies and developments of CAR-T therapy for AML.

Hassan G, Seno M. Blood and cancer: cancer stem cells as origin of hematopoietic cells in solid tumor microenvironments. Cells. 2020;9(5). https://doi.org/10.3390/cells9051293.

Newell LF, Cook RJ. Advances in acute myeloid leukemia BMJ. 2021;375:n2026. https://doi.org/10.1136/bmj.n2026.CrossRefPubMed

Mo JS, Park HW, Guan KL. The Hippo signaling pathway in stem cell biology and cancer. EMBO Rep. 2014;15(6):642–56. https://doi.org/10.15252/embr.201438638.CrossRefPubMedPubMedCentral

Bishop MR, Maziarz RT, Waller EK, Jäger U, Westin JR, McGuirk JP, Fleury I, Holte H, Borchmann P, Del Corral C, et al. Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion. Blood Adv. 2019;3(14):2230–6. https://doi.org/10.1182/bloodadvances.2019000151.CrossRefPubMedPubMedCentral

June CH, Sadelain M. Chimeric Antigen receptor therapy. N Engl J Med. 2018;379(1):64–73. https://doi.org/10.1056/NEJMra1706169.CrossRefPubMedPubMedCentral

Maus MV, Levine BL. Chimeric antigen receptor T-cell therapy for the community oncologist. Oncologist. 2016;21(5):608–17. https://doi.org/10.1634/theoncologist.2015-0421.CrossRefPubMedPubMedCentral

Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 2019;34:45–55. https://doi.org/10.1016/j.blre.2018.11.002.CrossRefPubMed

Jin X, Zhang M, Sun R, Lyu H, Xiao X, Zhang X, Li F, Xie D, Xiong X, Wang J, et al. First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia. J Hematol Oncol. 2022;15(1):88. https://doi.org/10.1186/s13045-022-01308-1.CrossRefPubMedPubMedCentral

Tabata R, Chi S, Yuda J, Minami Y. Emerging immunotherapy for acute myeloid leukemia. Int J Mol Sci 2021;22(4). https://doi.org/10.3390/ijms22041944.

10.

Marofi F, Rahman HS, Al-Obaidi ZMJ, Jalil AT, Abdelbasset WK, Suksatan W, Dorofeev AE, Shomali N, Chartrand MS, Pathak Y, et al. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients. Stem Cell Res Ther. 2021;12(1):465. https://doi.org/10.1186/s13287-021-02420-8.CrossRefPubMedPubMedCentral

11.

Sauer T, Parikh K, Sharma S, Omer B, Sedloev D, Chen Q, Angenendt L, Schliemann C, Schmitt M, Müller-Tidow C, et al. CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. Blood. 2021;138(4):318–30. https://doi.org/10.1182/blood.2020008221.CrossRefPubMedPubMedCentral

12.

Papalexi E, Satija R. Single-cell RNA sequencing to explore immune cell heterogeneity. Nat Rev Immunol. 2018;18(1):35–45. https://doi.org/10.1038/nri.2017.76.CrossRefPubMed

13.

• Gottschlich A, Thomas M, Grünmeier R, Lesch S, Rohrbacher L, Igl V, Briukhovetska D, Benmebarek MR, Vick B, Dede S, et al. Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia. Nat Biotechnol. 2023. https://doi.org/10.1038/s41587-023-01684-0. An novel and systematic method (single-cell transcription) was used and reported to select adapt antigens of AML.

14.

Hebbar N, Epperly R, Vaidya A, Thanekar U, Moore SE, Umeda M, Ma J, Patil SL, Langfitt D, Huang S, et al. CAR T cells redirected to cell surface GRP78 display robust anti-acute myeloid leukemia activity and do not target hematopoietic progenitor cells. Nat Commun. 2022;13(1):587. https://doi.org/10.1038/s41467-022-28243-6.CrossRefPubMedPubMedCentral

15.

Gumber D, Wang LD. Improving CAR-T immunotherapy: overcoming the challenges of T cell exhaustion. EBioMedicine. 2022;77:103941. https://doi.org/10.1016/j.ebiom.2022.103941.CrossRefPubMedPubMedCentral

16.

Trad R, Warda W, Alcazer V, Neto da Rocha M, Berceanu A, Nicod C, Haderbache R, Roussel X, Desbrosses Y, Daguindau E, et al. Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia. J Immunother Cancer. 2022;10(7). https://doi.org/10.1136/jitc-2021-004222.

17.

Li Z, Deng M, Huang F, Jin C, Sun S, Chen H, Liu X, He L, Sadek AH, Zhang CC. LILRB4 ITIMs mediate the T cell suppression and infiltration of acute myeloid leukemia cells. Cell Mol Immunol. 2020;17(3):272–82. https://doi.org/10.1038/s41423-019-0321-2.CrossRefPubMed

18.

Deng M, Gui X, Kim J, Xie L, Chen W, Li Z, He L, Chen Y, Chen H, Luo W, et al. LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature. 2018;562(7728):605–9. https://doi.org/10.1038/s41586-018-0615-z.CrossRefPubMedPubMedCentral

19.

John S, Chen H, Deng M, Gui X, Wu G, Chen W, Li Z, Zhang N, An Z, Zhang CC. A novel anti-LILRB4 CAR-T cell for the treatment of monocytic AML. Mol Ther. 2018;26(10):2487–95. https://doi.org/10.1016/j.ymthe.2018.08.001.CrossRefPubMedPubMedCentral

20.

Lemoine J, Ruella M, Houot R. Born to survive: how cancer cells resist CAR T cell therapy. J Hematol Oncol. 2021;14(1):199. https://doi.org/10.1186/s13045-021-01209-9.CrossRefPubMedPubMedCentral

21.

Daver N, Alotaibi AS, Bücklein V, Subklewe M. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. Leukemia. 2021;35(7):1843–63. https://doi.org/10.1038/s41375-021-01253-x.CrossRefPubMedPubMedCentral

22.

Xie B, Li Z, Zhou J, Wang W. Current status and perspectives of dual-targeting chimeric antigen receptor T-cell therapy for the treatment of hematological malignancies. Cancers (Basel) 2022;14(13). https://doi.org/10.3390/cancers14133230.

23.

Mei H, Li C, Jiang H, Zhao X, Huang Z, Jin D, Guo T, Kou H, Liu L, Tang L, et al. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. J Hematol Oncol. 2021;14(1):161. https://doi.org/10.1186/s13045-021-01170-7.CrossRefPubMedPubMedCentral

24.

Wang Y, Yang Y, Hong R, Zhao H, Wei G, Wu W, Xu H, Cui J, Zhang Y, Chang AH, et al. A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia. Blood Cancer J. 2020;10(10):105. https://doi.org/10.1038/s41408-020-00371-6.CrossRefPubMedPubMedCentral

25.

Tong C, Zhang Y, Liu Y, Ji X, Zhang W, Guo Y, Han X, Ti D, Dai H, Wang C, et al. Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma. Blood. 2020;136(14):1632–44. https://doi.org/10.1182/blood.2020005278.CrossRefPubMedPubMedCentral

26.

Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA, Krueger W, Worden AA, Kadan MJ, Yim S, et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med. 2020;26(10):1569–75. https://doi.org/10.1038/s41591-020-1081-3.CrossRefPubMed

27.

Dai H, Wu Z, Jia H, Tong C, Guo Y, Ti D, Han X, Liu Y, Zhang W, Wang C, et al. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J Hematol Oncol. 2020;13(1):30. https://doi.org/10.1186/s13045-020-00856-8.CrossRefPubMedPubMedCentral

28.

Liu F, Cao Y, Pinz K, Ma Y, Wada M, Chen K, Ma G, Shen J, Tse CO, Su Y. First-in-human CLL1-CD33 compound CAR T cell therapy induces complete remission in patients with refractory acute myeloid leukemia: update on phase 1 clinical trial. Blood. 2018;132:901.CrossRef

29.

Antar AI, Otrock ZK, Jabbour E, Mohty M, Bazarbachi A. FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions. Leukemia. 2020;34(3):682–96. https://doi.org/10.1038/s41375-019-0694-3.CrossRefPubMed

30.

Li KX, Wu HY, Pan WY, Guo MQ, Qiu DZ, He YJ, Li YH, Yang DH, Huang YX. A novel approach for relapsed/refractory FLT3(mut+) acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib. Mol Cancer. 2022;21(1):66. https://doi.org/10.1186/s12943-022-01541-9.CrossRefPubMedPubMedCentral

31.

Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, Straathof K, Liu E, Durett AG, Grilley B, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365(18):1673–83. https://doi.org/10.1056/NEJMoa1106152.CrossRefPubMedPubMedCentral

32.

Tiberghien P, Ferrand C, Lioure B, Milpied N, Angonin R, Deconinck E, Certoux JM, Robinet E, Saas P, Petracca B, et al. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood. 2001;97(1):63–72. https://doi.org/10.1182/blood.v97.1.63.CrossRefPubMed

33.

Agliardi G, Liuzzi AR, Hotblack A, De Feo D, Núñez N, Stowe CL, Friebel E, Nannini F, Rindlisbacher L, Roberts TA, et al. Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma. Nat Commun. 2021;12(1):444. https://doi.org/10.1038/s41467-020-20599-x.CrossRefPubMedPubMedCentral

34.

Zhang H, Savage S, Schultz AR, Bottomly D, White L, Segerdell E, Wilmot B, McWeeney SK, Eide CA, Nechiporuk T, et al. Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. Nat Commun. 2019;10(1):244. https://doi.org/10.1038/s41467-018-08263-x.CrossRefPubMedPubMedCentral

35.

Ruella M, Maus MV. Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies. Comput Struct Biotechnol J. 2016;14:357–62. https://doi.org/10.1016/j.csbj.2016.09.003.CrossRefPubMedPubMedCentral

36.

Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 2014;20(2):119–22. https://doi.org/10.1097/ppo.0000000000000035.CrossRefPubMedPubMedCentral

37.

Perez K, Walsh R, Brilliant K, Noble L, Yakirevich E, Breese V, Jackson C, Chatterjee D, Pricolo V, Roth L, et al. Heterogeneity of colorectal cancer (CRC) in reference to KRAS proto-oncogene utilizing WAVE technology. Exp Mol Pathol. 2013;95(1):74–82. https://doi.org/10.1016/j.yexmp.2013.01.004.CrossRefPubMedPubMedCentral

38.

Flugel CL, Majzner RG, Krenciute G, Dotti G, Riddell SR, Wagner DL, Abou-El-Enein M. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol. 2023;20(1):49–62. https://doi.org/10.1038/s41571-022-00704-3.CrossRefPubMed

39.

Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19(3):185–99. https://doi.org/10.1038/s41573-019-0051-2.CrossRefPubMed

40.

Liu Y, Liu G, Wang J, Zheng ZY, Jia L, Rui W, Huang D, Zhou ZX, Zhou L, Wu X, et al. Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors. Sci Transl Med. 2021;13(586). https://doi.org/10.1126/scitranslmed.abb5191.

41.

Wilkie S, van Schalkwyk MC, Hobbs S, Davies DM, van der Stegen SJ, Pereira AC, Burbridge SE, Box C, Eccles SA, Maher J. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol. 2012;32(5):1059–70. https://doi.org/10.1007/s10875-012-9689-9.CrossRefPubMed

42.

Zhang E, Yang P, Gu J, Wu H, Chi X, Liu C, Wang Y, Xue J, Qi W, Sun Q, et al. Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy. J Hematol Oncol. 2018;11(1):102. https://doi.org/10.1186/s13045-018-0646-9.CrossRefPubMedPubMedCentral

43.

Vaupel P, Multhoff G. Revisiting the Warburg effect: historical dogma versus current understanding. J Physiol. 2021;599(6):1745–57. https://doi.org/10.1113/jp278810.CrossRefPubMed

44.

Tabe Y, Yamamoto S, Saitoh K, Sekihara K, Monma N, Ikeo K, Mogushi K, Shikami M, Ruvolo V, Ishizawa J, et al. Bone marrow adipocytes facilitate fatty acid oxidation activating AMPK and a transcriptional network supporting survival of acute monocytic leukemia cells. Cancer Res. 2017;77(6):1453–64. https://doi.org/10.1158/0008-5472.Can-16-1645.CrossRefPubMedPubMedCentral

45.

Shafat MS, Oellerich T, Mohr S, Robinson SD, Edwards DR, Marlein CR, Piddock RE, Fenech M, Zaitseva L, Abdul-Aziz A, et al. Leukemic blasts program bone marrow adipocytes to generate a protumoral microenvironment. Blood. 2017;129(10):1320–32. https://doi.org/10.1182/blood-2016-08-734798.CrossRefPubMed

46.

Michalek RD, Gerriets VA, Jacobs SR, Macintyre AN, MacIver NJ, Mason EF, Sullivan SA, Nichols AG, Rathmell JC. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J Immunol. 2011;186(6):3299–303. https://doi.org/10.4049/jimmunol.1003613.CrossRefPubMed

47.

Rohner A, Langenkamp U, Siegler U, Kalberer CP, Wodnar-Filipowicz A. Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis. Leuk Res. 2007;31(10):1393–402. https://doi.org/10.1016/j.leukres.2007.02.020.CrossRefPubMed

48.

Zhang W, He Q, Lopez B, Hu J, Kundu A, Andraza MC, Kerner AR, Schreiber GH, Shepard HM, Frost GI. Abstract PO074: logic-gating HER2 CAR-T to the tumor microenvironment mitigates on-target, off-tumor toxicity without compromising cytotoxicity against HER2-over-expressing tumors. Cancer Immunol Res. 2021;9(2_Supplement):PO074–PO074.CrossRef

49.

Juillerat A, Marechal A, Filhol JM, Valogne Y, Valton J, Duclert A, Duchateau P, Poirot L. An oxygen sensitive self-decision making engineered CAR T-cell. Sci Rep. 2017;7:39833. https://doi.org/10.1038/srep39833.CrossRefPubMedPubMedCentral

50.

Dumas SJ, Meta E, Borri M, Luo Y, Li X, Rabelink TJ, Carmeliet P. Phenotypic diversity and metabolic specialization of renal endothelial cells. Nat Rev Nephrol. 2021;17(7):441–64. https://doi.org/10.1038/s41581-021-00411-9.CrossRefPubMedPubMedCentral

51.

Han X, Bryson PD, Zhao Y, Cinay GE, Li S, Guo Y, Siriwon N, Wang P. Masked chimeric antigen receptor for tumor-specific activation. Mol Ther. 2017;25(1):274–84. https://doi.org/10.1016/j.ymthe.2016.10.011.CrossRefPubMedPubMedCentral

52.

Zhang JL, Morrell G, Rusinek H, Warner L, Vivier PH, Cheung AK, Lerman LO, Lee VS. Measurement of renal tissue oxygenation with blood oxygen level-dependent MRI and oxygen transit modeling. Am J Physiol Renal Physiol. 2014;306(6):F579-587. https://doi.org/10.1152/ajprenal.00575.2013.CrossRefPubMedPubMedCentral

53.

Richards RM, Zhao F, Freitas KA, Parker KR, Xu P, Fan A, Sotillo E, Daugaard M, Oo HZ, Liu J, et al. NOT-gated CD93 CAR T cells effectively target AML with minimized endothelial cross-reactivity. Blood Cancer Discov. 2021;2(6):648–65. https://doi.org/10.1158/2643-3230.Bcd-20-0208.CrossRefPubMedPubMedCentral

54.

Fedorov VD, Themeli M, Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med. 2013;5(215):215ra172. https://doi.org/10.1126/scitranslmed.3006597.CrossRefPubMedPubMedCentral

55.

He X, Feng Z, Ma J, Ling S, Cao Y, Gurung B, Wu Y, Katona BW, O’Dwyer KP, Siegel DL, et al. Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia. Blood. 2020;135(10):713–23. https://doi.org/10.1182/blood.2019002779.CrossRefPubMedPubMedCentral

56.

Purbhoo MA, Irvine DJ, Huppa JB, Davis MM. T cell killing does not require the formation of a stable mature immunological synapse. Nat Immunol. 2004;5(5):524–30. https://doi.org/10.1038/ni1058.CrossRefPubMed

57.

Sykulev Y, Joo M, Vturina I, Tsomides TJ, Eisen HN. Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity. 1996;4(6):565–71. https://doi.org/10.1016/s1074-7613(00)80483-5.CrossRefPubMed

58.

Mansilla-Soto J, Eyquem J, Haubner S, Hamieh M, Feucht J, Paillon N, Zucchetti AE, Li Z, Sjöstrand M, Lindenbergh PL, et al. HLA-independent T cell receptors for targeting tumors with low antigen density. Nat Med. 2022;28(2):345–52. https://doi.org/10.1038/s41591-021-01621-1.CrossRefPubMedPubMedCentral

59.

Baeuerle PA, Ding J, Patel E, Thorausch N, Horton H, Gierut J, Scarfo I, Choudhary R, Kiner O, Krishnamurthy J, et al. Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response. Nat Commun. 2019;10(1):2087. https://doi.org/10.1038/s41467-019-10097-0.CrossRefPubMedPubMedCentral

60.

Xu Y, Yang Z, Horan LH, Zhang P, Liu L, Zimdahl B, Green S, Lu J, Morales JF, Barrett DM, et al. A novel antibody-TCR (AbTCR) platform combines Fab-based antigen recognition with gamma/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release. Cell Discov. 2018;4:62. https://doi.org/10.1038/s41421-018-0066-6.CrossRefPubMedPubMedCentral

61.

Helsen CW, Hammill JA, Lau VWC, Mwawasi KA, Afsahi A, Bezverbnaya K, Newhook L, Hayes DL, Aarts C, Bojovic B, et al. The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity. Nat Commun. 2018;9(1):3049. https://doi.org/10.1038/s41467-018-05395-y.CrossRefPubMedPubMedCentral

62.

Naik J, Themeli M, de Jong-Korlaar R, Ruiter RWJ, Poddighe PJ, Yuan H, de Bruijn JD, Ossenkoppele GJ, Zweegman S, Smit L, et al. CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia. Haematologica. 2019;104(3):e100–3. https://doi.org/10.3324/haematol.2018.192757.CrossRefPubMedPubMedCentral

63.

Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, Syed K, Liu K, van de Donk NW, Weiss BM, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128(3):384–94. https://doi.org/10.1182/blood-2015-12-687749.CrossRefPubMedPubMedCentral

64.

•• Amini L, Silbert SK, Maude SL, Nastoupil LJ, Ramos CA, Brentjens RJ, Sauter CS, Shah NN, Abou-El-Enein M. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nat Rev Clin Oncol. 2022;19(5):342–355. https://doi.org/10.1038/s41571-022-00607-3. Providing a systematical review of the current limitations and an outlook of CAR-T therapy.

65.

Katsarou A, Sjöstrand M, Naik J, Mansilla-Soto J, Kefala D, Kladis G, Nianias A, Ruiter R, Poels R, Sarkar I, et al. Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence. Sci Transl Med. 2021;13(623):eabh1962. https://doi.org/10.1126/scitranslmed.abh1962.CrossRefPubMedPubMedCentral

66.

Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449–59. https://doi.org/10.1056/NEJMoa1709919.CrossRefPubMedPubMedCentral

67.

Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126(6):2123–38. https://doi.org/10.1172/jci85309.CrossRefPubMedPubMedCentral

68.

Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517–28. https://doi.org/10.1016/s0140-6736(14)61403-3.CrossRefPubMed

69.

Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, Boesteanu AC, Wang Y, O’Connor RS, Hwang WT, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24(5):563–71. https://doi.org/10.1038/s41591-018-0010-1.CrossRefPubMedPubMedCentral

70.

Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, Bagg A, Marcucci KT, Shen A, Gonzalez V, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7(303):303ra139. https://doi.org/10.1126/scitranslmed.aac5415.CrossRefPubMedPubMedCentral

71.

•• Tettamanti S, Pievani A, Biondi A, Dotti G, Serafini M. Catch me if you can: how AML and its niche escape immunotherapy. Leukemia. 2022;36(1):13–22. https://doi.org/10.1038/s41375-021-01350-x. The mechanism of immune escape in the treatment of AML was elucidated which is meaningful(for the innovation and exploration in the area of treating AML.)

72.

Turner JA, Stephen-Victor E, Wang S, Rivas MN, Abdel-Gadir A, Harb H, Cui Y, Fanny M, Charbonnier LM, Fong JJH, et al. Regulatory T cell-derived TGF-β1 controls multiple checkpoints governing allergy and autoimmunity. Immunity. 2020;53(6):1202-1214.e1206. https://doi.org/10.1016/j.immuni.2020.10.002.CrossRefPubMedPubMedCentral

73.

Mansour I, Zayed RA, Said F, Latif LA. Indoleamine 2,3-dioxygenase and regulatory T cells in acute myeloid leukemia. Hematology. 2016;21(8):447–53. https://doi.org/10.1080/10245332.2015.1106814.CrossRefPubMed

74.

Lu Y, Liu J, Liu Y, Qin Y, Luo Q, Wang Q, Duan H. TLR4 plays a crucial role in MSC-induced inhibition of NK cell function. Biochem Biophys Res Commun. 2015;464(2):541–7. https://doi.org/10.1016/j.bbrc.2015.07.002.CrossRefPubMed

75.

Dimitri A, Herbst F, Fraietta JA. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing. Mol Cancer. 2022;21(1):78. https://doi.org/10.1186/s12943-022-01559-z.CrossRefPubMedPubMedCentral

76.

Mali P, Esvelt KM, Church GM. Cas9 as a versatile tool for engineering biology. Nat Methods. 2013;10(10):957–63. https://doi.org/10.1038/nmeth.2649.CrossRefPubMedPubMedCentral

77.

Liang C, Huang S, Zhao Y, Chen S, Li Y. TOX as a potential target for immunotherapy in lymphocytic malignancies. Biomark Res. 2021;9(1):20. https://doi.org/10.1186/s40364-021-00275-y.CrossRefPubMedPubMedCentral

78.

Jiang W, He Y, He W, Wu G, Zhou X, Sheng Q, Zhong W, Lu Y, Ding Y, Lu Q, et al. Exhausted CD8+T cells in the tumor immune microenvironment: new pathways to therapy. Front Immunol. 2020;11:622509. https://doi.org/10.3389/fimmu.2020.622509.CrossRefPubMed

79.

Lynn RC, Weber EW, Sotillo E, Gennert D, Xu P, Good Z, Anbunathan H, Lattin J, Jones R, Tieu V, et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature. 2019;576(7786):293–300. https://doi.org/10.1038/s41586-019-1805-z.CrossRefPubMedPubMedCentral

80.

Chen J, López-Moyado IF, Seo H, Lio CJ, Hempleman LJ, Sekiya T, Yoshimura A, Scott-Browne JP, Rao A. NR4A transcription factors limit CAR T cell function in solid tumours. Nature. 2019;567(7749):530–4. https://doi.org/10.1038/s41586-019-0985-x.CrossRefPubMedPubMedCentral

81.

Kawalekar OU, O’Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD Jr, Patel PR, Guedan S, Scholler J, Keith B, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity. 2016;44(2):380–90. https://doi.org/10.1016/j.immuni.2016.01.021.CrossRefPubMed

82.

Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara VR, et al. 4–1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21(6):581–90. https://doi.org/10.1038/nm.3838.CrossRefPubMedPubMedCentral

83.

Zhang W, Shi L, Zhao Z, Du P, Ye X, Li D, Cai Z, Han J, Cai J. Disruption of CTLA-4 expression on peripheral blood CD8 + T cell enhances anti-tumor efficacy in bladder cancer. Cancer Chemother Pharmacol. 2019;83(5):911–20. https://doi.org/10.1007/s00280-019-03800-x.CrossRefPubMed

84.

Zhang Y, Zhang X, Cheng C, Mu W, Liu X, Li N, Wei X, Liu X, Xia C, Wang H. CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells. Front Med. 2017;11(4):554–62. https://doi.org/10.1007/s11684-017-0543-6.CrossRefPubMed

85.

Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res. 2017;23(9):2255–66. https://doi.org/10.1158/1078-0432.Ccr-16-1300.CrossRefPubMed

86.

Sterner RM, Sakemura R, Cox MJ, Yang N, Khadka RH, Forsman CL, Hansen MJ, Jin F, Ayasoufi K, Hefazi M, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2019;133(7):697–709. https://doi.org/10.1182/blood-2018-10-881722.CrossRefPubMedPubMedCentral

87.

Odé Z, Condori J, Peterson N, Zhou S, Krenciute G. CRISPR-mediated non-viral site-specific gene integration and expression in T cells: protocol and application for T-cell therapy. Cancers (Basel) 2020;12(6). https://doi.org/10.3390/cancers12061704.

88.

Spoo AC, Lübbert M, Wierda WG, Burger JA. CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood. 2007;109(2):786–91. https://doi.org/10.1182/blood-2006-05-024844.CrossRefPubMed

89.

Rees HA, Liu DR. Base editing: precision chemistry on the genome and transcriptome of living cells. Nat Rev Genet. 2018;19(12):770–88.CrossRefPubMedPubMedCentral

90.

Gaudelli NM, Komor AC, Rees HA, Packer MS, Badran AH, Bryson DI, Liu DR. Programmable base editing of A• T to G• C in genomic DNA without DNA cleavage. Nature. 2017;551(7681):464–71.CrossRefPubMedPubMedCentral

91.

Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016;533(7603):420–4. https://doi.org/10.1038/nature17946.CrossRefPubMedPubMedCentral

92.

Gaudelli NM, Lam DK, Rees HA, Solá-Esteves NM, Barrera LA, Born DA, Edwards A, Gehrke JM, Lee SJ, Liquori AJ, et al. Directed evolution of adenine base editors with increased activity and therapeutic application. Nat Biotechnol. 2020;38(7):892–900. https://doi.org/10.1038/s41587-020-0491-6.CrossRefPubMed

93.

Mamonkin M, Rouce RH, Tashiro H, Brenner MK. A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood. 2015;126(8):983–92. https://doi.org/10.1182/blood-2015-02-629527.CrossRefPubMedPubMedCentral

94.

Diorio C, Murray R, Naniong M, Barrera L, Camblin A, Chukinas J, Coholan L, Edwards A, Fuller T, Gonzales C, et al. Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL. Blood. 2022;140(6):619–29. https://doi.org/10.1182/blood.2022015825.CrossRefPubMedPubMedCentral

95.

Haber AL, Biton M, Rogel N, Herbst RH, Shekhar K, Smillie C, Burgin G, Delorey TM, Howitt MR, Katz Y, et al. A single-cell survey of the small intestinal epithelium. Nature. 2017;551(7680):333–9. https://doi.org/10.1038/nature24489.CrossRefPubMedPubMedCentral

96.

Pietrobon V, Todd LA, Goswami A, Stefanson O, Yang Z, Marincola F. Improving CAR T-cell persistence. Int J Mol Sci. 2021;22(19). https://doi.org/10.3390/ijms221910828.

97.

Chen C, Liang C, Wang S, Chio CL, Zhang Y, Zeng C, Chen S, Wang C, Li Y. Expression patterns of immune checkpoints in acute myeloid leukemia. J Hematol Oncol. 2020;13(1):28. https://doi.org/10.1186/s13045-020-00853-x.CrossRefPubMedPubMedCentral

98.

Rotiroti MC, Buracchi C, Arcangeli S, Galimberti S, Valsecchi MG, Perriello VM, Rasko T, Alberti G, Magnani CF, Cappuzzello C, et al. Targeting CD33 in chemoresistant AML patient-derived xenografts by CAR-CIK cells modified with an improved SB transposon system. Mol Ther. 2020;28(9):1974–86. https://doi.org/10.1016/j.ymthe.2020.05.021.CrossRefPubMedPubMedCentral

99.

Kenderian SS, Ruella M, Shestova O, Klichinsky M, Kim MY, Porter DL, June CH, Gill SI. Identification of PD1 and TIM3 as checkpoints that limit chimeric antigen receptor T cell efficacy in leukemia. Blood. 2015;126(23):852.CrossRef

100.

Weber EW, Lynn RC, Sotillo E, Lattin J, Xu P, Mackall CL. Pharmacologic control of CAR-T cell function using dasatinib. Blood Adv. 2019;3(5):711–7. https://doi.org/10.1182/bloodadvances.2018028720.CrossRefPubMedPubMedCentral

101.

Mestermann K, Giavridis T, Weber J, Rydzek J, Frenz S, Nerreter T, Mades A, Sadelain M, Einsele H, Hudecek M. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. Sci Transl Med 2019;11(499). https://doi.org/10.1126/scitranslmed.aau5907.

102.

Zhang H, Hu Y, Shao M, Teng X, Jiang P, Wang X, Wang H, Cui J, Yu J, Liang Z, et al. Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion. J Hematol Oncol. 2021;14(1):113. https://doi.org/10.1186/s13045-021-01117-y.CrossRefPubMedPubMedCentral

103.

Nian Z, Zheng X, Dou Y, Du X, Zhou L, Fu B, Sun R, Tian Z, Wei H. Rapamycin pretreatment rescues the bone marrow AML cell elimination capacity of CAR-T cells. Clin Cancer Res. 2021;27(21):6026–38. https://doi.org/10.1158/1078-0432.Ccr-21-0452.CrossRefPubMedPubMedCentral

104.

Leclercq G, Haegel H, Toso A, Zimmermann T, Green L, Steinhoff N, Sam J, Pulko V, Schneider A, Giusti AM, et al. JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy. J Immunother Cancer. 2022;10(1). https://doi.org/10.1136/jitc-2021-003766.

105.

Funk CR, Wang S, Chen KZ, Waller A, Sharma A, Edgar CL, Gupta VA, Chandrakasan S, Zoine JT, Fedanov A, et al. PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity. Blood. 2022;139(4):523–37. https://doi.org/10.1182/blood.2021011597.CrossRefPubMedPubMedCentral

106.

Esfahani K, Al-Aubodah TA, Thebault P, Lapointe R, Hudson M, Johnson NA, Baran D, Bhulaiga N, Takano T, Cailhier JF, et al. Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation. Nat Commun. 2019;10(1):4712. https://doi.org/10.1038/s41467-019-12628-1.CrossRefPubMedPubMedCentral

107.

Huye LE, Nakazawa Y, Patel MP, Yvon E, Sun J, Savoldo B, Wilson MH, Dotti G, Rooney CM. Combining mTor inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination. Mol Ther. 2011;19(12):2239–48. https://doi.org/10.1038/mt.2011.179.CrossRefPubMedPubMedCentral

108.

Ghoneim HE, Fan Y, Moustaki A, Abdelsamed HA, Dash P, Dogra P, Carter R, Awad W, Neale G, Thomas PG, et al. De novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation. Cell. 2017;170(1):142-157.e119. https://doi.org/10.1016/j.cell.2017.06.007.CrossRefPubMedPubMedCentral

109.

Finelli C, Follo MY, Stanzani M, Parisi S, Clissa C, Mongiorgi S, Barraco M, Cocco L. Clinical impact of hypomethylating agents in the treatment of myelodysplastic syndromes. Curr Pharm Des. 2016;22(16):2349–57. https://doi.org/10.2174/1381612822666160310145040.CrossRefPubMed

110.

Daniel FI, Cherubini K, Yurgel LS, de Figueiredo MA, Salum FG. The role of epigenetic transcription repression and DNA methyltransferases in cancer. Cancer. 2011;117(4):677–87. https://doi.org/10.1002/cncr.25482.CrossRefPubMed

111.

El Khawanky N, Hughes A, Yu W, Myburgh R, Matschulla T, Taromi S, Aumann K, Clarson J, Vinnakota JM, Shoumariyeh K, et al. Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia. Nat Commun. 2021;12(1):6436. https://doi.org/10.1038/s41467-021-26683-0.CrossRefPubMedPubMedCentral

112.

Leick MB, Silva H, Scarfò I, Larson R, Choi BD, Bouffard AA, Gallagher K, Schmidts A, Bailey SR, Kann MC, et al. Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia. Cancer Cell. 2022;40(5):494-508.e495. https://doi.org/10.1016/j.ccell.2022.04.001.CrossRefPubMedPubMedCentral

113.

Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol. 2009;27:83–117. https://doi.org/10.1146/annurev.immunol.021908.132544.CrossRefPubMed

114.

Cao X, Jin X, Zhang X, Utsav P, Zhang Y, Guo R, Lu W, Zhao M. Small-molecule compounds boost CAR-T cell therapy in hematological malignancies. Curr Treat Options Oncol. 2023;24(3):184–211. https://doi.org/10.1007/s11864-023-01049-4.CrossRefPubMedPubMedCentral

115.

Jetani H, Navarro-Bailón A, Maucher M, Frenz S, Verbruggen C, Yeguas A, Vidriales MB, González M, Rial Saborido J, Kraus S, et al. Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia. Blood. 2021;138(19):1830–42. https://doi.org/10.1182/blood.2020009192.CrossRefPubMedPubMedCentral

116.

Abbott RC, Hughes-Parry HE, Jenkins MR. To go or not to go? Biological logic gating engineered T cells. J Immunother Cancer 2022;10(4). https://doi.org/10.1136/jitc-2021-004185.

117.

Giuffrida L, Sek K, Henderson MA, Lai J, Chen AXY, Meyran D, Todd KL, Petley EV, Mardiana S, Mølck C, et al. CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy. Nat Commun. 2021;12(1):3236. https://doi.org/10.1038/s41467-021-23331-5.CrossRefPubMedPubMedCentral

Titel: Developing Strategies to Improve the Efficacy of CAR-T Therapy for Acute Myeloid Leukemia
verfasst von: Shujing Guo, MMed
Xuejin Gao, MD
Mahara Sadhana, MMed
Ruiting Guo, MMed
Jile Liu, MMed
Wenyi Lu, MD
Ming Feng Zhao, MD
Publikationsdatum: 23.10.2023
Verlag: Springer US
Erschienen in: Current Treatment Options in Oncology / Ausgabe 11/2023
Print ISSN: 1527-2729
Elektronische ISSN: 1534-6277
DOI: https://doi.org/10.1007/s11864-023-01140-w

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Developing Strategies to Improve the Efficacy of CAR-T Therapy for Acute Myeloid Leukemia

Opinion statement

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Opinion statement

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2023

The Crying Need for a Better Response Assessment in Rectal Cancer

Systemic Therapy in Advanced Pleomorphic Liposarcoma: a Comprehensive Review

Radiotherapy for Advanced Esophageal Cancer: from Palliation to Curation

Sequencing Systemic Therapy in Hepatocellular Carcinoma

Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer

The Role of Liver Transplantation in the Treatment of Liver Metastases from Neuroendocrine Tumors

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie